Maplight Therapeutics, INC 10-Q quarterly reports

MapLight Therapeutics announced increased R&D and G&A expenses for Q2 2026, alongside positive clinical trial updates for ML-007C-MA and ML-004, while also planning a $150M private placement.

MapLight Therapeutics, Inc. reported a net loss of $60.7 million for the first quarter of 2026, with increased R&D expenses driving the results.

MapLight Therapeutics, a clinical-stage biopharmaceutical company, successfully completed its initial public offering and concurrent private placement in October 2025, raising approximately $269.8 million in net proceeds to fund its central nervous system disorder pipeline through 2027.